"Anaemia is the most common manifestation of myelodysplastic syndrome (MDS).In addition to replacement therapy, MDS-related anaemia can also be managed with erythropoiesis-stimulating proteins (ESPs) in monotherapy or in combination with granulocyte colony-stimulating factor (G-CSF): epoietin alfa or beta in standard doses(30,000\u201340,000 U weekly), high doses (60,000\u201380,000 U weekly), darbopoetin (150\u2013300 mcg per week) or in combination with G-CSF (300\u2013600 mcg per week). When erythroid response rates were evaluated using the International Working Group criteria (IWGc), there was a statistically significant difference in both groups compared to patients with supportive care. The combination with G-CSF particularly increases the response rates in patients with RARS (up to 70 %) and affects the survival compared to untreated patients. The best response to ESP treatment (with or without G-CSF) was found in low risk MDS patients(IPSS 0-1),low level of endogenous EPO (< 500 U) and need . . . . "RIV/00064165:_____/10:8117!RIV11-MZ0-00064165" . "An\u00E9mie je nej\u010Dast\u011Bj\u0161\u00EDm p\u0159\u00EDznakem myelodysplastick\u00E9ho syndromu (MDS). Krom\u011B substitu\u010Dn\u00ED l\u00E9\u010Dby je mo\u017En\u00E9 ovlivnit an\u00E9mii MDS tak\u00E9 erytropo\u00E9zu stimuluj\u00EDc\u00EDmi proteiny (EPS) v monoterapii nebo v kombinaci s r\u016Fstov\u00FDm faktorem pro granulocyt\u00E1rn\u00ED \u0159adu (G-CSF): epoetin alfa, resp. beta ve standardn\u00EDch d\u00E1vk\u00E1ch (30 000\u201340 000 U/t\u00FDden), ve vysok\u00FDch d\u00E1vk\u00E1ch (60 000\u201380 000 U/t\u00FDden), darbopoetin(150\u2013300 ug/t\u00FDden), nebo v kombinaci s G-CSF (300\u2013600 ug/t\u00FDden). P\u0159i hodnocen\u00ED erytroidn\u00EDch odpov\u011Bd\u00ED podle krit\u00E9ri\u00ED Mezin\u00E1rodn\u00ED pracovn\u00ED skupiny (IWGc) je statisticky v\u00FDznamn\u00FD rozd\u00EDl u obou skupin proti pacient\u016Fm s podp\u016Frnou p\u00E9\u010D\u00ED. Kombinace s G-CSF zvy\u0161uje procento odpov\u011Bd\u00ED zejm\u00E9na u pacient\u016F s RARS (a\u017E na 70 %) a ovliv\u0148uje d\u00E9lku p\u0159e\u017Eit\u00ED ve srovn\u00E1n\u00ED s pacienty bez l\u00E9\u010Dby. Nejlep\u0161\u00ED odpov\u011B\u010F na l\u00E9\u010Dbu EPS (s nebo bez G-CSF) maj\u00ED MDS pacienti s n\u00EDzk\u00FDm rizikem (IPSS-1)s n\u00EDzkou hladinou endogenn\u00EDho EPO (< 500 IU/l) a malou nebo \u017E\u00E1dnou pot\u0159ebou transfuz\u00ED ( "An\u00E9mie je nej\u010Dast\u011Bj\u0161\u00EDm p\u0159\u00EDznakem myelodysplastick\u00E9ho syndromu (MDS). Krom\u011B substitu\u010Dn\u00ED l\u00E9\u010Dby je mo\u017En\u00E9 ovlivnit an\u00E9mii MDS tak\u00E9 erytropo\u00E9zu stimuluj\u00EDc\u00EDmi proteiny (EPS) v monoterapii nebo v kombinaci s r\u016Fstov\u00FDm faktorem pro granulocyt\u00E1rn\u00ED \u0159adu (G-CSF): epoetin alfa, resp. beta ve standardn\u00EDch d\u00E1vk\u00E1ch (30 000\u201340 000 U/t\u00FDden), ve vysok\u00FDch d\u00E1vk\u00E1ch (60 000\u201380 000 U/t\u00FDden), darbopoetin(150\u2013300 ug/t\u00FDden), nebo v kombinaci s G-CSF (300\u2013600 ug/t\u00FDden). P\u0159i hodnocen\u00ED erytroidn\u00EDch odpov\u011Bd\u00ED podle krit\u00E9ri\u00ED Mezin\u00E1rodn\u00ED pracovn\u00ED skupiny (IWGc) je statisticky v\u00FDznamn\u00FD rozd\u00EDl u obou skupin proti pacient\u016Fm s podp\u016Frnou p\u00E9\u010D\u00ED. Kombinace s G-CSF zvy\u0161uje procento odpov\u011Bd\u00ED zejm\u00E9na u pacient\u016F s RARS (a\u017E na 70 %) a ovliv\u0148uje d\u00E9lku p\u0159e\u017Eit\u00ED ve srovn\u00E1n\u00ED s pacienty bez l\u00E9\u010Dby. Nejlep\u0161\u00ED odpov\u011B\u010F na l\u00E9\u010Dbu EPS (s nebo bez G-CSF) maj\u00ED MDS pacienti s n\u00EDzk\u00FDm rizikem (IPSS-1)s n\u00EDzkou hladinou endogenn\u00EDho EPO (< 500 IU/l) a malou nebo \u017E\u00E1dnou pot\u0159ebou transfuz\u00ED ( "myelodysplastic syndrome; anaemia; erythropoetin; epoietin; darbopoeitin; granulocyte; stimulating factor"@en . "1802-4475" . . . "Onkologie" . "5"^^ . "1"^^ . "Treatment of anaemia with erythropoiesis-stimulating proteins in patients with myelodysplastic syndrome"@en . "L\u00E9\u010Dba an\u00E9mie erytropo\u00E9zu stimuluj\u00EDc\u00EDmi proteiny u pacient\u016F s myelodysplastick\u00FDm syndromem"@cs . "L\u00E9\u010Dba an\u00E9mie erytropo\u00E9zu stimuluj\u00EDc\u00EDmi proteiny u pacient\u016F s myelodysplastick\u00FDm syndromem" . . "1"^^ . "\u0160i\u0161kov\u00E1, Magda" . . . "[31B7ABDC106B]" . "CZ - \u010Cesk\u00E1 republika" . . . "2" . . . . "Treatment of anaemia with erythropoiesis-stimulating proteins in patients with myelodysplastic syndrome"@en . "268105" . "L\u00E9\u010Dba an\u00E9mie erytropo\u00E9zu stimuluj\u00EDc\u00EDmi proteiny u pacient\u016F s myelodysplastick\u00FDm syndromem"@cs . . "4" . "I, Z(MSM0021620808)" . "RIV/00064165:_____/10:8117" . . . . . "L\u00E9\u010Dba an\u00E9mie erytropo\u00E9zu stimuluj\u00EDc\u00EDmi proteiny u pacient\u016F s myelodysplastick\u00FDm syndromem" . .